Literature DB >> 23515722

On-pump or off-pump? Impact of risk scores in coronary artery bypass surgery.

Omar Asdrúbal Vilca Mejía1, Luiz Augusto Ferreira Lisboa, Luiz Boro Puig, Luiz Felipe Pinho Moreira, Luis Alberto Oliveira Dallan, Fabio Biscegli Jatene.   

Abstract

OBJECTIVE: Remain controversies about the use of cardiopulmonary bypass (CPB) in coronary artery bypass grafting (CABG). The aim of this study was to evaluate the impact of the 2000 Bernstein Parsonnet (2000BP) and EuroSCORE (EU) for choice CPB in CABG.
METHODS: 1.551 consecutive patients underwent CABG. CPB was used in 1.121 (72.3%) patients. The performance of 2000BP and EU was assessed by calibration, discrimination and correlation tests. For both risk scores, increasing the value of the score and presence of CPB were directly related to a higher risk of death (P<0.05). Therefore with these two variables was constructed a logistic regression model for each risk score, in order to determine in which value of score the presence of CPB increases significantly the risk of death.
RESULTS: The calibration, like the area under the ROC curve for the group with CPB [2000BP=0.80; EU=0.78] and without CPB [2000BP=0.81; EU=0.85] were appropriate. The Spearman correlation for groups with and without CPB was 0.66 (P<0.001) and 0.62 (P<0.001), respectively. Using the 2000BP, for a value>17.75 the presence of CPB increased the chance of death to 7.4 [CI 95% (4.4-12.3), P<0.0001]. With the EU, for a value >4.5 the presence of CPB increased the chance of death to 5.4 [CI 95% (3.3-9), P<0.0001].
CONCLUSION: In decision making, the 2000BP>17.75 or the EU>4.5 guide to identify patients who underwent CABG with CPB increases significantly the chance of death.

Entities:  

Mesh:

Year:  2012        PMID: 23515722     DOI: 10.5935/1678-9741.20120091

Source DB:  PubMed          Journal:  Rev Bras Cir Cardiovasc


  6 in total

1.  Early and Medium Outcomes of On-Pump Beating-Heart versus Off-Pump CABG in Patients with Moderate Left Ventricular Dysfunction.

Authors:  Weitie Wang; Yong Wang; Hulin Piao; Bo Li; Tiance Wang; Dan Li; Zhicheng Zhu; Rihao Xu; Kexiang Liu
Journal:  Braz J Cardiovasc Surg       Date:  2019 Jan-Feb

Review 2.  Off-Pump Coronary Artery Bypass Grafting; is it Still Relevant?

Authors:  Chima K P Ofoegbu; Rodgers M Manganyi
Journal:  Curr Cardiol Rev       Date:  2022

3.  Risk factors of atheromatous aorta in cardiovascular surgery.

Authors:  Fernando A Atik; Isaac Azevedo Silva; Claudio Ribeiro da Cunha
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Oct-Dec

4.  Off-pump versus On-pump Coronary Artery Bypass Grafting in Frail Patients: Study Protocol for the FRAGILE Multicenter Randomized Controlled Trial.

Authors:  Omar Asdrúbal Vilca Mejía; Michel Pompeu Barros Oliveira Sá; Maurilio Onofre Deininger; Luís Roberto Palma Dallan; Rodrigo Coelho Segalote; Marco Antonio Praça de Oliveira; Fernando Antibas Atik; Magaly Arrais Dos Santos; Pedro Gabriel Melo de Barros E Silva; Rodrigo Mussi Milani; Alexandre Ciappina Hueb; Rosangela Monteiro; Ricardo Carvalho Lima; Luiz Augusto Ferreira Lisboa; Luís Alberto Oliveira Dallan; John Puskas; Fabio Biscegli Jatene
Journal:  Braz J Cardiovasc Surg       Date:  2017 Sep-Oct

5.  Predictors of Postoperative Acute Kidney Injury after Coronary Artery Bypass Graft Surgery.

Authors:  Christian Ortega-Loubon; Manuel Fernández-Molina; Lucía Pañeda-Delgado; Pablo Jorge-Monjas; Yolanda Carrascal
Journal:  Braz J Cardiovasc Surg       Date:  2018 Jul-Aug

6.  Mortality risk prediction in high-risk patients undergoing coronary artery bypass grafting: Are traditional risk scores accurate?

Authors:  Maxim Goncharov; Omar Asdrúbal Vilca Mejia; Camila Perez de Souza Arthur; Bianca Maria Maglia Orlandi; Alexandre Sousa; Marco Antônio Praça Oliveira; Fernando Antibas Atik; Rodrigo Coelho Segalote; Marcos Gradim Tiveron; Pedro Gabriel Melo de Barros E Silva; Marcelo Arruda Nakazone; Luiz Augusto Ferreira Lisboa; Luís Alberto Oliveira Dallan; Zhe Zheng; Shengshou Hu; Fabio Biscegli Jatene
Journal:  PLoS One       Date:  2021-08-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.